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Effect of C1‐inhibitor in adults with mild asthma: A randomized 
controlled trial
To the Editor,
Several newly approved monoclonal antibodies targeting type 2 
inflammation have shown remarkable beneficial effects in patients 
with severe asthma. Biologics directed against IL‐5 (mepolizumab, 
reslizumab), IL‐5 receptor (benralizumab), or IL‐4 receptor α (dup‐
ilumab) have shown to reduce asthma exacerbation rate by about 
50%.1,2 Though promising, these drugs are unable to completely 
alleviate inflammation‐induced asthma symptoms. Moreover, a 
substantial subset of patients without a pronounced type 2 airway 
inflammation does not benefit from the currently available biolog‐
ics. Therefore, novel anti‐inflammatory treatments targeting other 
relevant asthma‐associated pathways are still warranted. In recent 
years, the complement system has been implicated in the pathogen‐
esis of type 2 asthma.3 Elevated levels of anaphylatoxins, activation 
products of the complement system, have been found in the airways 
of asthma patients following local allergen provocation.4 Functional 
roles for the anaphylatoxins in asthma have been established in 
experimental studies in mice, showing that these proinflammatory 
mediators act synergistically and drive allergic inflammation.3 C1‐in‐
hibitor (C1‐INH) is an endogenous protein with a pivotal regulatory 
function in the complement system by inhibiting both the classical 
and lectin pathways. We hypothesized that C1‐INH administration 
inhibits complement activation and attenuates allergen‐induced air‐
way eosinophilia in patients with mild asthma.
In this randomized, double‐blind, placebo‐controlled, parallel 
study, 24 adults with asthma and house dust mite (HDM) allergy 
received a continuous intravenous infusion with human plasma‐de‐
rived C1‐INH 100 U kg−1 h−1 or placebo followed after 2 hours by 
segmental challenge with HDM and lipopolysaccharide (LPS) in one 
lung and saline in the contralateral lung as control. Bronchoalveolar 
lavage fluid was obtained seven hours after HDM/LPS or saline chal‐
lenge. The primary outcome was influx of eosinophils and neutro‐
phils, defined as number of cells/mL, into the bronchoalveolar space. 
Further details of the study design, subject selection criteria, bron‐
choalveolar lavage handling, assays, and statistical analysis are de‐
scribed in the supplemental section. Baseline patient characteristics 
were similar across treatment groups (Table S1).
Two hours after the initiation of C1‐INH infusion, median plasma 
C1‐INH antigen concentrations were four times higher in C1‐INH‐
infused patients compared to vehicle‐infused controls (Figure S1A). 
Segmental HDM/LPS challenge resulted in increased C1‐INH anti‐
gen levels in BALF compared to saline instillation in both treatment 
groups (Figure S1C). C1‐INH concentrations were higher in BALF 
from C1‐INH‐infused patients compared to the placebo group. 
C1‐INH activity levels in plasma and BALF were similar to C1‐INH 
antigen concentrations (Figure S1B,D), indicating that C1‐INH was 
biologically active.
HDM/LPS challenge induced elevated C4a concentrations com‐
pared to saline challenge in the placebo group (Figure S2A). In the 
C1‐INH group, BALF C4a levels were similar between the saline 
and HDM/LPS‐challenged sites. Consistently, using an assay that 
detects the C4 activation products C4b, C4bi, and C4c (collectively 
referred to as C4bc), C4 activation in the lung subsegment exposed 
to HDM/LPS was increased in patients infused with placebo but not 
in those infused with C1‐INH (Figure S2B). We next measured the 
anaphylatoxin C3a, which is released following C3 cleaved activa‐
tion.5 Similar to C4a, HDM/LPS challenge increased BALF C3a in the 
placebo group, but not in the C1‐INH treatment group (Figure S2C). 
In agreement, C3 activation products were elevated in the HDM/
LPS‐challenged lung in patients infused with placebo but not in 
those administered with C1‐INH (Figure S2D). These data indicate 
that C1‐INH infusion prevents C4a and C3a generation in the air‐
ways upon a bronchial challenge with HDM/LPS.
HDM/LPS instillation augmented total cell counts in BALF com‐
pared to saline, partly as consequence of eosinophil and neutrophil 
influx (Figure 1A‐C). Likewise, HDM/LPS challenge elevated CD4 
T cells, but did not alter the number of alveolar macrophages in 
BALF (Figure S3A,B). C1‐INH did not modify this allergen‐induced 
response. HDM/LPS also induced degranulation of eosinophils and 
neutrophils in the bronchoalveolar space (Figure S4A‐D). These re‐
sponses were not affected by C1‐INH with the exception of lactofer‐
rin release, which was inhibited by C1‐INH (Figure S4B).
To obtain further insight into the inflammatory response upon 
HDM/LPS challenge and the effect of C1‐INH hereon, we mea‐
sured a broad spectrum of cytokines and chemokines relevant for 
allergic inflammation. Of the 35 cytokines and chemokines mea‐
sured, 15 were detectable in BALF (Table S2, Table S3). HDM/
LPS induced increases in neutrophil chemoattractants such as 
interleukin (IL)‐8, IL‐1β, tumor necrosis factor‐α, and macrophage 
inflammatory proteins 1α and 1β (Table S2). Likewise, eosinophil 
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attractants eotaxin‐1 and RANTES were increased upon HDM/
LPS challenge. These responses were not influenced by C1‐INH. 
HDM/LPS also induced the release of growth‐related oncogene‐α, 
stromal cell–derived factor‐1α, and IL‐18 in the placebo group. 
Although statistically insignificant, these rises were also detected 
in the C1‐INH group.
Beside the complement system, C1‐INH is an important regu‐
lator of the kallikrein‐kinin system due to its inhibitory effect on 
FXIIa and kallikrein activity.6 Elevated levels of kallikrein‐kinin sys‐
tem components have been documented in the airways of asthma 
patients.7 We determined C1‐INH/FXII and C1‐INH/kallikrein com‐
plexes as measure for kallikrein‐kinin system activation. In BALF, 
however, these complexes were below detection limit. Hence, the 
current challenge model is not suitable to study the contribution of 
the kallikrein‐kinin system in allergen‐induced inflammation and the 
effect of C1‐INH hereon.
Vascular leak often occurs as consequence of allergen‐induced 
inflammation in the airway of asthma patients8 and has been associ‐
ated with the loss of asthma control.9 We determined the quotients 
of albumin and α2‐macroglobulin levels in BALF and plasma (QAlb 
and QA2M, respectively) and the relative coefficient of excretion 
(QA2M/QAlb) as measures of the permeability of the blood‐airway 
barrier.4 Intrabronchial HDM/LPS challenge was associated with 
significant increase in QAlb (Figure 2A), QA2M (Figure 2B), and 
relative coefficient of excretion (Figure 2C) in the placebo group. 
These effects were abrogated in the C1‐INH group (Figure 2A‐C). 
Likewise, HDM/LPS induced elevated BALF IgM concentrations 
in placebo‐infused patients but not in C1‐INH‐treated subjects 
(Figure 2D).
In conclusion, we show that intravenous C1‐INH administration 
prior to intrabronchial HDM/LPS challenge prevents complement 
activation and vascular leak without attenuating allergic lung inflam‐
mation in patients with HDM allergy and asthma. Suppressing vas‐
cular leakage could help improve symptoms in patients who do not 
respond adequately to currently available drugs.
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F I G U R E  1   Intravenous C1‐inhibitor infusion does not modify leukocyte influx after HDM/LPS challenge in the airways of asthma 
patients. A, Total cell number in BALF, B, eosinophils in BALF, C, neutrophils in BALF. Data represent the median with interquartile range, the 
smallest and largest observation. **: P < .01, ***: P < .001, BALF: bronchoalveolar lavage
F I G U R E  2   Intravenous C1‐inhibitor 
infusion reduces vascular leak following 
HDM/LPS challenge in the airways of 
asthma patients. A, Qalbumin: BALF 
albumin/plasma albumin, B, Qα2‐
macroglobulin: BALF α2‐macroglobulin/
plasma α2‐macroglobulin, C, Relative 
coefficient of excretion (RCE): Qα2M/
Qalbumin, (D) BALF IgM levels. Data 
represent the median with interquartile 
range, the smallest and largest 
observation. **: P < .01, ***: P < .001, ns: 
not significant, BALF: bronchoalveolar 
lavage
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